Home » Stocks » Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc. (PVCT)

Stock Price: $0.0899 USD -0.0039 (-4.16%)
Updated Aug 13, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 35.12M
Revenue (ttm) n/a
Net Income (ttm) -6.82M
Shares Out 390.69M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $0.0899
Previous Close $0.0938
Change ($) -0.0039
Change (%) -4.16%
Day's Open 0.0919
Day's Range 0.0880 - 0.0937
Day's Volume 239,083
52-Week Range 0.0300 - 0.1300

More Stats

Market Cap 35.12M
Enterprise Value 56.51M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 390.69M
Float 373.50M
EPS (basic) -0.01
EPS (diluted) -0.02
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.82M
Short Ratio 0.47
Short % of Float 0.78%
Beta 0.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.44
Revenue n/a
Operating Income -5.32M
Net Income -6.82M
Free Cash Flow -4.32M
Net Cash -21.39M
Net Cash / Share -0.05
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -162.75%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.0899
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-6.30-8.05-13.32-24.95-24.65-16.81-13.03-14.34-21.44-20.69
Net Income-6.92-8.15-13.52-24.43-24.50-10.24-27.70-12.57-19.43-18.55
Shares Outstanding38738236923419617613211310678.82
Earnings Per Share-0.02-0.02-0.04-0.12-0.13-0.06-0.22-0.11-0.19-0.37
Operating Cash Flow-6.19-5.20-10.35-21.94-17.41-13.85-9.89-11.26-17.20-13.73
Capital Expenditures---0.03--0.01-0.07-0.01-0.02-0.01-
Free Cash Flow-6.19-5.20-10.38-21.94-17.42-13.92-9.90-11.27-17.21-13.73
Cash & Equivalents0.590.050.111.1714.1817.3915.701.227.718.09
Total Debt20.3713.939.46-------
Net Cash / Debt-19.78-13.88-9.351.1714.1817.3915.701.227.718.09
Book Value-24.07-17.42-10.023.4716.3225.196.634.3910.0210.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Provectus Biopharmaceuticals, Inc.
Country United States
Employees 2
CEO Bruce Horowitz

Stock Information

Ticker Symbol PVCT
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: PVCT


Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.